SME · NSE EmergeListed
Avience Biomedicals Ltd. IPO: dates, price band, lot size, objects of the issue
Get analyst updates on this IPO
Analyst updates come by email.What changed since listing, from SEBI-registered research analysts.
By continuing you agree to the Terms and Privacy policy
Key facts
- Lot amount at the upper band
- ₹1,24,800
- Computed from the issue price (Prospectus dated Tue 23 Jun 2026, page 3)
- Issue size at the upper band
- ₹30.24 crore
Timeline (IST)
- OpensThu 18 Jun 2026, 10:00 am IST confirmedProspectus dated Tue 23 Jun 2026, page 1
- ClosesMon 22 Jun 2026 confirmedProspectus dated Tue 23 Jun 2026, page 1
- UPI mandate cut-offMon 22 Jun 2026, 5:00 pm IST confirmedProspectus dated Tue 23 Jun 2026, page 1
- AllotmentTue 23 Jun 2026 confirmedProspectus dated Tue 23 Jun 2026, page 429
- Refund and unblockWed 24 Jun 2026 confirmedProspectus dated Tue 23 Jun 2026, page 429
- Shares to dematWed 24 Jun 2026 confirmedProspectus dated Tue 23 Jun 2026, page 429
- ListingThu 25 Jun 2026 confirmedProspectus dated Tue 23 Jun 2026, page 429
Objects of the issue
| Object | Amount |
|---|---|
| Part finances the capital expenditure towards setting up of a new manufacturing unit at industrial plot no. 70, Sector 28 in the Medical Device Park under the Yamuna Expressway Industrial Development Authority (YEIDA), Gautam Buddha Nagar, Uttar Pradesh | ₹14.05 crore |
| Funding the working capital requirement of our Company | ₹8.25 crore |
| General Corporate Purposes | ₹3.97 crore |
| Total | ₹26.27 crore |
Prospectus dated Tue 23 Jun 2026, page 99
Company and promoters
As described in the prospectus
Avience Biomedicals has expanded its product range from IVD rapid test kits to include a comprehensive line of medical devices such as Serology products, Biochemistry Analyser and Biochemistry Reagents, showcasing a dedication to addressing various healthcare needs.
Prospectus dated Tue 23 Jun 2026, page 23
Promoters
- 4 individual promoters
Prospectus dated Tue 23 Jun 2026, page 23
Shareholding
| Holding | Before the issue | After the issue |
|---|---|---|
| Promoters and promoter group | 87.89% | 64.59% |
Prospectus dated Tue 23 Jun 2026, page 93
Financials (restated)
| Item | January 31, 2026 | March 31, 2025 | March 31, 2024 |
|---|---|---|---|
| Revenue from operations | ₹41.84 crore | ₹45.24 crore | ₹23.96 crore |
| Profit after tax | ₹5.74 crore | ₹7.23 crore | ₹2.14 crore |
| Net worth | ₹28.52 crore | ₹22.78 crore | ₹6.21 crore |
| Total borrowings | ₹26.73 crore | ₹22.16 crore | ₹15.13 crore |
Prospectus dated Tue 23 Jun 2026, page 67
Risk factors
94 total- The company operates in a heavily regulated market and failing to comply with rules could lead to litigation or other liabilities (offer document page 33)
- A portion of revenue comes from a few customers, and losing a major customer could hurt the business (offer document page 33)
- The company relies on outside suppliers for trading goods and for raw materials and components, and supply disruptions could hurt operations (offer document page 34)
- The business needs a large amount of working capital, and not meeting that need could hurt results (offer document page 36)
- Some raw materials are imported from China, so import restrictions or duties could affect the business (offer document page 37)
All 94 risk factors, pages 32 to 63
Offer document
Allotment and bids
Registrar to the issue: SKYLINE FINANCIAL SERVICES PRIVATE LIMITED.
Allotment status is on the registrar's site, from Tue 23 Jun 2026. Pick "Avience Biomedicals Ltd." from the issue list there.